Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
N/A
Completed
NCT05323994
| Condition | Depression, COVID-19 |
|---|
| Phase | N/A |
|---|
| Sponsor | Servier Russia |
|---|
| Status | Completed |
|---|
| Enrollment | 104 participants |
|---|
| Start date | Apr 19, 2022 |
|---|
| Completion date | Feb 20, 2023 |
|---|
| Results posted | Oct 17, 2024 |
|---|
Summary
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks of treatment. 10 clinics and 10 of psychiatrists and neurologists across the country will participate in the study and it is estimated that each investigating physician will enroll 10 patients.
Antidepressive Effectiveness of Agomelatine in Patients With Depression Episode Occurred After COVID-19 Assessed by HAMD-17 After 8 Weeks of Treatment in the Daily Clinical Practice.
8 weeks · score on a scale
| Patients With Depression Occurred After COVID 19 | 10.9 ± 4.90 score on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.